BA BA - Hemostemix President, CoFounder

All Insiders . USA . 
Stock . Hemostemix . Stakeholders . Insider . BA BA
HMTXF Stock  USD 0.07  0.0001  0.15%   

Insider

BA BA is President, CoFounder of Hemostemix
Age 61
Phone403-506-3373
Webhttps://www.hemostemix.com

Hemostemix Management Efficiency

The company has return on total asset (ROA) of (2.4947) % which means that it has lost $2.4947 on every $100 spent on assets. This is way below average. Hemostemix's management efficiency ratios could be used to measure how well Hemostemix manages its routine affairs as well as how well it operates its assets and liabilities.
Hemostemix has accumulated 1.48 M in total debt. Hemostemix has a current ratio of 0.28, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Hemostemix until it has trouble settling it off, either with new capital or with free cash flow. So, Hemostemix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hemostemix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hemostemix to invest in growth at high rates of return. When we think about Hemostemix's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

INSIDER Age

Andreas BergthalerHookipa Pharma
N/A
Klaus OrlingerHookipa Pharma
47
BSc MACell Source
73
Eli GoldbergerImmunoCellular Therapeutics
33
Wayne CPAImmunoCellular Therapeutics
69
Reinhard KanderaHookipa Pharma
55
BS MSImmunoCellular Therapeutics
66
Marine PopoffHookipa Pharma
N/A
Shalom MDImmunoCellular Therapeutics
87
Lukas FlatzHookipa Pharma
N/A
Christine MBAHookipa Pharma
59
Joern AldagHookipa Pharma
65
Prof MDHookipa Pharma
81
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix is traded on OTC Exchange in the United States. Hemostemix [HMTXF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Asset-2.49

Hemostemix Leadership Team

Elected by the shareholders, the Hemostemix's board of directors comprises two types of representatives: Hemostemix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hemostemix. The board's role is to monitor Hemostemix's management team and ensure that shareholders' interests are well served. Hemostemix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hemostemix's outside directors are responsible for providing unbiased perspectives on the board's policies.
BA BA, President, CoFounder
MD Sr, Chief Officer
Thomas CA, Pres Inc
Peter Pavlin, VP Operations
Cameron Cole, Head Relations
Christina CPA, Interim Officer

Hemostemix Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Hemostemix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-2.49
Current Valuation9.27 M
Shares Outstanding75.74 M
Shares Owned By Insiders12.40 %
Price To Book39.23 X
EBITDA(6.53 M)
Net Income(6.29 M)
Cash And Equivalents649.32 K
Cash Per Share0.01 X
Total Debt1.48 M

Currently Active Assets on Macroaxis

GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft
GOOGAlphabet Inc Class C
GMGeneral Motors

Other Information on Investing in Hemostemix OTC Stock

Hemostemix financial ratios help investors to determine whether Hemostemix OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hemostemix with respect to the benefits of owning Hemostemix security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY